Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, A.
  • Vazquez, I.
  • Cuenca, I.
  • Rosa-Rosa, J.M.|||0000-0003-0806-6453
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Jimenez, C.
  • Fernandez-Mercado, M.
  • Larrayoz, M.J.
  • Gutierrez, N.C.
  • Fernandez-Guijarro, M.
  • Gonzalez-Calle, V.
  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Alegre, Adrian|||0000-0002-2423-822X
  • Escalante, F.
  • de la Rubia, Javier|||0000-0002-8354-768X
  • Teruel, A.I.
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Lopez-Jimenez, Javier|||0000-0002-2969-3002
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Puig, Noemí|||0000-0001-7535-3861
  • Paiva, Bruno|||0000-0003-1977-3815
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Calasanz, M.J.|||0000-0002-0374-3008
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Rios, R.
  • Sureda, Anna|||0000-0002-1238-6970
  • Blanchard, María Jesús
  • Martinez-Martinez, R.
  • Moraleda, J. M.
  • Bargay, Joan|||0000-0002-6739-3916
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Palomera, L.
  • Gonzalez-Montes, Y.
  • Martí, J.M.
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Arguiñano, J.M.
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Gonzalez, A.P.
  • Casado Montero, Luis Felipe|||0000-0002-8171-0674
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
Dipòsit Digital de Documents de la UAB
Publicación

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

  • Martín-Sánchez, Esperanza
  • Blanco Fernández, Laura|||0000-0002-1859-0884
  • Kim, Peter S.
  • Bisht, Kamlesh
  • Wang, Hongfang|||0000-0002-1104-1540
  • Van de Velde, Helgi
  • Jelinek, Tomas
  • Simoes, Catia
  • Prosper, Felipe|||0000-0001-6115-8790
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Alfonso-Piérola, Ana|||0000-0002-2478-5354
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Rodríguez-Veiga, Rebeca|||0000-0003-2139-8540
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Montesinos, Pau|||0000-0002-3275-5593
  • Paiva, Bruno|||0000-0003-1977-3815
  • Zabaleta, Aintzane|||0000-0003-3474-3040
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

  • Aguirre-Ruiz, Paula
  • Ariceta, Beñat
  • Viguria Alegría, María Cruz
  • Zudaire, María Teresa
  • Blasco-Iturri, Zuriñe
  • Arnedo, Patricia
  • Aguilera-Diaz, Almudena
  • Jauregui, Axier
  • Mañú, Amagoia
  • Prósper, Felipe
  • Mateos, María Carmen
  • Fernández-Mercado, Marta
  • Larráyoz, María José
  • Redondo, Margarita
  • Calasanz, María José
  • Bandrés Elizalde, Eva
  • Vázquez Urio, Iria
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect early relapse are needed. We hypothesized that the use of next generation sequencing (NGS) could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis, we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR) chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable for the evaluation of patients following HSCT and highly valuable to personalized early treatment intervention when mixed chimerism is detected., This work was funded by the Government of Navarra, Department of Industry, Energy and Innovation (Project DIANA, 0011-1411-2017-000028); and supported by CIMA LAB diagnostics research program. F.P. acknowledges funding from Instituto de Salud Carlos III (ISCIII) PI16/02024, PI17/00701 and PI19/01352 (Co-financed with European Union FEDER funds), CIBERONC CB16/12/00489 (Co-financed with European Union FEDER funds), MINECO Explora (RTHALMY), Departamento de Salud-Gobierno de Navarra 40/2016 and Fundación Ramón Areces (PREMAMM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

  • Larrayoz, Marta
  • García-Barcina, María
  • Celay, Jon
  • Etxebeste, Amaia
  • Jimenez, Maddalen
  • Perez, Cristina
  • Ordoñez, Raquel
  • Cobaleda, Cesar
  • Botta, Cirino
  • Fresquet, Vicente
  • Roa, Sergio
  • Goicoechea, Ibai
  • Maia, Catarina
  • Lasaga, Miren
  • Chesi, Marta
  • Bergsagel, P Leif
  • Larrayoz, Maria J
  • Calasanz, Maria J
  • Campos-Sanchez, Elena
  • Martinez-Cano, Jorge
  • Panizo, Carlos
  • Rodriguez-Otero, Paula
  • Vicent, Silvestre
  • Roncador, Giovanna
  • Gonzalez, Patricia
  • Takahashi, Satoru
  • Katz, Samuel G
  • Walensky, Loren D
  • Ruppert, Shannon M
  • Lasater, Elisabeth A
  • Amann, Maria
  • Lozano, Teresa
  • Llopiz, Diana
  • Sarobe, Pablo
  • Lasarte, Juan J
  • Planell, Nuria
  • Gomez-Cabrero, David
  • Kudryashova, Olga
  • Kurilovich, Anna
  • Revuelta, Maria V
  • Cerchietti, Leandro
  • Agirre, Xabier
  • San Miguel, Jesus
  • Paiva, Bruno
  • Prosper, Felipe
  • Martinez-Climent, Jose A
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of ∼500 mice and ∼1,000 patients revealed a common MAPK–MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8 T cells with reduced immunosuppressive regulatory T (T) cells, while late MYC acquisition in slow progressors was associated with lower CD8 T cell infiltration and more abundant T cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8 T cells versus T cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8 T/T cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therap, This work was supported by the imCORE Network on behalf of F. Hoffmann-La Roche (NAV4 and NAV15 projects). Additional support was obtained from Spanish Ministry of Health - Instituto de Salud Carlos III (FIS), grants PI19/00818, PI20/00048, PI20/00260, CIBERONC no. CB16/12/00489 and no. CB16/12/00369, with support from FEDER (Fondo Europeo de Desarrollo Regional); Paula and Rodger Riney Foundation; Accelerator Award Program from the Spanish Association Against Cancer (AECC), Cancer Research United Kingdom (CRUK), and Associazione Italiana per la Ricerca sul Cancro (AIRC); Spanish Ministry of Education and Science, grants SAF2017-83061-R, PLEC2021-008094, and PID2021-128283OA; Fundacion Arnal Planelles; Fundacion Ramon Areces; Banco de Santander; European Research Council Starting Grant (MYELOMANEXT); CRIS Cancer Foundation (PR_EX_2020-02); AICR grant 24534, 2021; and Leukemia Lymphoma Society. M.C. and P.L.B. were supported by RO1 CA234181. L.C. was supported by R01 CA242069. M.L. was supported by a junior investigator grant from AECC. M.J.G.-B. was supported by Fundacion Arnal Planelles. J.C. was supported by AECC through the ‘Accelerator’ Award. S.R. was supported by RYC-2014-16399/MEC. J.M.C. is the recipient of an FPU fellowship from Universidad Autonoma de Madrid.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

  • Sanoja-Flores, L.
  • Flores-Montero, J.
  • Garces, J.J.
  • Paiva, B.
  • Puig, N.
  • Garcia-Mateo, A.
  • Garcia-Sanchez, O.
  • Corral-Mateos, A.
  • Burgos, L.
  • Blanco, E.
  • Hernandez-Martin, J.
  • Pontes, R.
  • Diez-Campelo, M.
  • Millacoy, P.
  • Rodriguez-Otero, P.
  • Prosper, F.
  • Merino, J.
  • Vidriales, M.B.
  • Garcia-Sanz, R.
  • Romero, A.
  • Palomera, L.
  • Rios-Tamayo, R.
  • Perez-Andres, M.
  • Blanco, J.F.
  • Gonzalez, M.
  • van Dongen, J.J.M.
  • Durie, B.
  • Mateos, M.V.
  • San-Miguel, J.
  • Orfao, A.
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p < 0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p < 0.0001) and a shorter survival in MM patients with active disease requiring treatment (p <= 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Otros (Other)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

  • Cuenca, I.
  • Alameda, D.
  • Sanchez-Vega, B.
  • Gomez-Sanchez, D.
  • Alignani, D.
  • Lasa, M.
  • Onecha, E.
  • Lecumberri, R.
  • Prosper, F.
  • Ocio, E.M.
  • González, M.E.
  • García de Coca, A.
  • De La Rubia, J.
  • Gironella, M.
  • Palomera, L.
  • Oriol, A.
  • Casanova, M.
  • Cabañas, V.
  • Taboada, F.
  • Pérez-Montaña, A.
  • De Arriba, F.
  • Puig, N.
  • Carreño-Tarragona, G.
  • Barrio, S.
  • Enrique de la Puerta, J.
  • Ramirez-Payer, A.
  • Krsnik, I.
  • Bargay, J.J.
  • Lahuerta, J.J.
  • Mateos, M.V.
  • San-Miguel, J.F.
  • Paiva, B.
  • Lopez, J.M.
To the Editor: Sequence-based analysis has come to play an integral role in many hematological malignancies [1], but disorders such as systemic light-chain (AL) amyloidosis remain poorly characterized due to its low incidence and small tumor size [2, 3]. Thus, greater knowledge about the immunogenetic landscape of AL amyloidosis is required since, for example, potential differences between the genomic profiles of AL amyloidosis and multiple myeloma (MM) could help identifying patients with monoclonal gammopathies at greater risk of developing AL amyloidosis and monitor presymptomatic organ damage [4, 5]. To gain further insight into the immunogenetic landscape of AL amyloidosis, we performed whole-exome sequencing (WES) on highly purified bone marrow clonal plasma cells (PCs) isolated by fluorescence activation cell sorting (FACS) based on patient-specific aberrant phenotypes. A total of 27 patients with confirmed new diagnosis of AL amyloidosis based on the presence of amyloid-related systemic syndrome, positive amyloid tissue staining with Congo red, restricted light-chain deposition by immunohistochemistry or mass spectometry, and evidence of PC clonality were investigated. Patients’ demographics and clinical characteristics are described in Supplementary Table 1. PCs were collected and processed in triplicates followed by whole genome amplification of samples with genomic DNA amounts <50 ng (Supplementary Table 2). Afterwards, library construction, exome enrichment, and sequencing were performed individually. An overall average depth of 63× and mean on-target coverage of 84% were obtained. Data were deposited in the Sequence Read Archive of the NCBI (http://www.ncbi.nlm.nih.gov/sra) under the PRJNA596656 access number...
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Fabrication of human myocardium using multidimensional modelling of engineered tissues

  • Montero-Calle, Pilar
  • Flandes-Iparraguirre, María
  • Mountris, Konstantinos
  • S de la Nava, Ana
  • Laita, Nicolás
  • Rosales, Ricardo M
  • Iglesias-García, Olalla
  • de-Juan-Pardo, Elena M
  • Atienza, Felipe
  • Fernández-Santos, María Eugenia
  • Peña, Estefanía
  • Doblaré, Manuel
  • Gavira, Juan J
  • Fernández-Avilés, Francisco
  • Prósper, Felipe
  • Pueyo, Esther
  • Mazo, Manuel M
Biofabrication of human tissues has seen a meteoric growth triggered by recent technical advancements such as human induced pluripotent stem cells (hiPSCs) and additive manufacturing. However, generation of cardiac tissue is still hampered by lack of adequate mechanical properties and crucially by the often unpredictable post-fabrication evolution of biological components. In this study we employ melt electrowriting (MEW) and hiPSC-derived cardiac cells to generate fibre-reinforced human cardiac minitissues. These are thoroughly characterized in order to build computational models and simulations able to predict their post-fabrication evolution. Our results show that MEW-based human minitissues display advanced maturation 28 post-generation, with a significant increase in the expression of cardiac genes such as MYL2, GJA5, SCN5A and the MYH7/MYH6 and MYL2/MYL7 ratios. Human iPSC-cardiomyocytes are significantly more aligned within the MEW-based 3D tissues, as compared to conventional 2D controls, and also display greater expression of C ×43. These are also correlated with a more mature functionality in the form of faster conduction velocity. We used these data to develop simulations capable of accurately reproducing the experimental performance. In-depth gauging of the structural disposition (cellular alignment) and intercellular connectivity (C ×43) allowed us to develop an improved computational model able to predict the relationship between cardiac cell alignment and functional performance. This study lays down the path for advancing in the development of in silico tools to predict cardiac biofabricated tissue evolution after generation, and maps the route towards more accurate and biomimetic tissue manufacture.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García Gómez, Antonio
  • Li, Tianlu|||0000-0001-7152-4870
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Martín Sánchez, Montserrat
  • San Segundo, Laura|||0000-0003-2391-5935
  • Muntión, Sandra|||0000-0001-7164-0767
  • Morales Urteaga, Xabier|||0000-0003-0303-9958
  • Ortiz de Solórzano, Carlos|||0000-0001-8720-0205
  • Oyarzabal, Julen|||0000-0003-1941-7255
  • San José Enériz, Edurne|||0000-0001-5786-5273
  • Esteller, M|||0000-0003-4490-6093
  • Agirre, Xabier|||0000-0002-6558-9560
  • Prosper, Felipe|||0000-0001-6115-8790
  • Garayoa, Mercedes|||0000-0003-2194-2841
  • Ballestar, Esteban|||0000-0002-1400-2440
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

  • Garreta, Elena|||0000-0002-1071-9794
  • Prado, Patricia|||0000-0003-2225-9948
  • Stanifer, Megan|||0000-0002-5606-1297
  • Monteil, Vanessa|||0000-0002-2652-5695
  • Marco Giménez, Andrés|||0000-0002-9831-8433
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Moya Rull, Daniel|||0000-0002-3555-6477
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Tarantino, Carolina|||0000-0003-2470-3803
  • Romero, Juan Pablo|||0000-0002-0441-4791
  • Jonsson, Gustav|||0000-0001-6692-8395
  • Oria, Roger
  • Leopoldi, Alexandra
  • Hagelkruys, Astrid
  • Gallo, Maria|||0000-0001-9099-7235
  • González Grassi, Federico|||0000-0002-7147-2246
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Gavaldà i Navarro, Aleix|||0000-0001-8421-3174
  • Hurtado del Pozo, Carmen
  • Hasan Ali, Omar|||0000-0001-5185-7520
  • Ventura-Aguiar, Pedro|||0000-0003-3381-7503
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Prosper, Felipe|||0000-0001-6115-8790
  • Mirazimi, Ali|||0000-0003-2371-6055
  • Boulant, Steeve|||0000-0001-8614-4993
  • Penninger, Josef|||0000-0002-8194-3777
  • Montserrat, Nuria
It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. Upon SARS-CoV-2 infection, diabetic-like kidney organoids exhibited higher viral loads compared with their control counterparts. Genetic deletion of the angiotensin-converting enzyme 2 (ACE2) in kidney organoids under control or diabetic-like conditions prevented viral detection. Moreover, cells isolated from kidney biopsies from diabetic patients exhibited altered mitochondrial respiration and enhanced glycolysis, resulting in higher SARS-CoV-2 infections compared with non-diabetic cells. Conversely, the exposure of patient cells to dichloroacetate (DCA), an inhibitor of aerobic glycolysis, resulted in reduced SARS-CoV-2 infections. Our results provide insights into the identification of diabetic-induced metabolic programming in the kidney as a critical event increasing SARS-CoV-2 infection susceptibility, opening the door to the identification of new interventions in COVID-19 pathogenesis targeting energy metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

  • Lasaga, Miren
  • Río, Paula
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Planell, Núria
  • Navarro, Susana|||0000-0002-6753-546X
  • Alignani, Diego
  • Fernández-Varas, Beatriz
  • Mouzo, Daniel
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Nicoletti, Eileen
  • Schwartz, Jonathan D.
  • Sevilla, Julián|||0000-0002-6852-1860
  • Ainciburi, Marina
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Surralles, Jordi|||0000-0002-4041-7519
  • Perona, Rosario|||0000-0002-2973-5153
  • Sastre, Leandro|||0000-0003-3613-5938
  • Prosper, Felipe|||0000-0001-6115-8790
  • Gomez-Cabrero, David
  • Bueren, Juan|||0000-0002-3228-7013
Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in non-conditioned Fanconi anemia (FA) patients resulting from the proliferative advantage of corrected FA hematopoietic stem and progenitor cells (HSPC). However, it is not yet known if gene therapy can revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPC co-existing in the BM of gene therapy-treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC. This includes a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases; in this case, in FA characterized by BMF and cancer predisposition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

  • Serrano, Guillermo|||0000-0003-3972-6186
  • Berastegui, Nerea|||0000-0002-9868-0547
  • Díaz-Mazkiaran, Aintzane
  • García-Olloqui, Paula|||0000-0002-7983-2875
  • Rodriguez-Res, Carmen
  • Huerga-Dominguez, Sofia
  • Ainciburu, Marina|||0000-0001-6483-1901
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Martin-Uriz, Patxi San|||0000-0003-1483-4279
  • Aguirre-Ruiz, Paula
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Lamo-Espinosa, Jose-Maria
  • Acha, Pamela|||0000-0002-4528-1219
  • Calvete, Oriol|||0000-0002-2623-2876
  • Jimenez, Tamara|||0000-0001-5894-2023
  • Molero, Antonieta|||0000-0002-3735-465X
  • Montoro Gómez, Maria Julia|||0000-0001-9532-7417
  • Diez-Campelo, María|||0000-0002-1467-6779
  • Valcárcel, David|||0000-0002-8747-078X
  • Sole, F.|||0000-0002-3251-2161
  • Alfonso-Piérola, Ana|||0000-0002-2478-5354
  • Ochoa, Idoia|||0000-0003-1864-7868
  • Prosper, Felipe|||0000-0001-6115-8790
  • Ezponda, Teresa|||0000-0003-3682-7125
  • Hernaez, Mikel|||0000-0003-0443-2305
While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34 + progenitors from del(5q) MDS patients, we have identified cells harboring the deletion, characterizing the transcriptional impact of this genetic insult on disease pathogenesis and treatment response. Interestingly, both del(5q) and non-del(5q) cells present similar transcriptional lesions, indicating that all cells, and not only those harboring the deletion, may contribute to aberrant hematopoietic differentiation. However, gene regulatory network (GRN) analyses reveal a group of regulons showing aberrant activity that could trigger altered hematopoiesis exclusively in del(5q) cells, pointing to a more prominent role of these cells in disease phenotype. In del(5q) MDS patients achieving hematological response upon lenalidomide treatment, the drug reverts several transcriptional alterations in both del(5q) and non-del(5q) cells, but other lesions remain, which may be responsible for potential future relapses. Moreover, lack of hematological response is associated with the inability of lenalidomide to reverse transcriptional alterations. Collectively, this study reveals transcriptional alterations that could contribute to the pathogenesis and treatment response of del(5q) MDS. The hematopoiesis of patients with del(5q) Myelodysplastic Syndromes is composed of a mixture of cells with and without the deletion. Here, the authors show that del(5q) and non-del(5q) cells share similar transcriptional alterations, with del(5q) cells presenting additional lesions. Moreover, hematological response to lenalidomide is associated with the reversal of some transcriptional lesions in both del(5q) and non-del(5q) cells.